ArticleAnnals of Saudi medicine
The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis.
Article in Annals of Saudi medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Diagnostic value of anti-cyclic citrullinated peptide antibody combined with rheumatoid factor in rheumatoid arthritis in Asia: a meta-analysis.The Journal of international medical research · 2021Pooled it
- The role of autoantibodies in post-chikungunya viral arthritis disease severity.Microbiology spectrum · 2025Article
- Reactivity of Rheumatoid Arthritis-Associated Citrulline-Dependent Antibodies to Epstein-Barr Virus Nuclear Antigen1-3.Antibodies (Basel, Switzerland) · 2022Article
- Association of interleukin-17A rs2275913 polymorphism with rheumatoid arthritis susceptibility in Sudanese population.SAGE open medicine · 2021Article
- The Utility and Experience with Disease Biomarkers in Juvenile Onset Arthritis vs. Adult Onset Arthritis.Cureus · 2019Review
- Observational
- Determinants of pain in patients with symptomatic knee osteoarthritis.Caspian journal of internal medicine · 2016Review
- Discriminative and diagnostic value of anti-cyclic citrullinated peptide antibodies in Iranian patients with rheumatoid arthritis.Rheumatology international · 2013Article
- The status of serum vitamin D in patients with rheumatoid arthritis and undifferentiated inflammatory arthritis compared with controls.Rheumatology international · 2012Article
- Rheumatoid Arthritis: Early diagnosis and treatment outcomes.Caspian journal of internal medicine · 2011Article
- A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis.Autoimmune diseases · 2011Article
- Diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody for rheumatoid arthritis.Rheumatology international · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe utility of anticyclic citrullinated peptide (anti-CCP) antibody in the diagnosis of rheumatoid arthritis (RA) varies across different studies. We determined the diagnostic performance and predictive ability of anti-CCP for RA.
methodsWe studied 201 patients with RA and compared them with 208 non-RA patients as controls. RA patients included in the study fulfilled the American College of Rheumatology revised criteria and patients with other diseases as well as those with undifferentiated arthritis (UIA) were used as controls. Anti-CCP was measured by enzyme-linked immunosorbent assay (ELISA) and rheumatoid factor (RF) by the agglutination method. The optimal cutoff value and diagnostic accuracy were determined using receiver operating characteristics (ROC) curve and area under the curve (AUC).The sensitivity and specificity were determined by comparison of RA patients with non-RA controls.
resultsThe anti-CCP test was positive in 164 patients with RA for a sensitivity of 81.6%, specificity of 87.5%, and overall accuracy of 84.6%. The respective values for RF were 75.6%, 86.5% and 84.4%. The anti-CCP test discriminated RA from non-RA patients with high accuracy (AUC=0.889 [0.017] 95% CI, 0.856-0.952, P=.001), and predicted progression of UIA to RA with moderate accuracy (AUC=0.733 [0.069], 95% CI 0.60-0.87, P<.006) at a sensitivity of 75% and a specificity of 68.1%. Among 60 UIA patients, in 16 (26.7%) who differentiated to RA, the mean (standard deviation) for anti-CPP was significantly higher than in 24 (40%) patients who progressed to non-RA (134.8 [172] vs 46 [86] U/mL, P<.01).
conclusionThese findings indicate that anti-CCP yields higher sensitivity and overall accuracy, but slightly greater specificity than RF for diagnosis of RA. Anti-CCP positivity, particularly a higher level of serum antibody in patients with UIA, may be a predictor of subsequent RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.